ROIV Roivant Sciences Ltd.
Health Care, filed as ROIVANT SCIENCES LTD (SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
Bought by 2 managers in 2026 Q3, sold by 3
In 2026 Q3, 2 managers added, 2 trimmed, and 1 sold out.
Who owns this now
Largest portfolio weights among holders, up to 3.4% (Farallon Capital Management). Not free-float ownership.
Who owns ROIV
Sorted by value, long equity only, as of 2026 Q3. Exits show their last held size.
| History | |||||
|---|---|---|---|---|---|
| Farallon Capital Management | Add +52.0% | 21,745,533 | $795M | History | |
| Andreas Halvorsen, Viking Global Investors | Add +7.7% | 6,757,326 | $247M | History | |
| Lee Ainslie, Maverick Capital | Reduce −18.4% | 2,307,799 | $84M | History | |
| David Einhorn, DME Capital Management | Reduce −47.4% | 1,131,747 | $41M | History | |
| Ron Baron, BAMCO Inc. (Baron Capital) | Hold | 125,000 | $4.6M | History | |
| Polen Capital Management exited 2026 Q3 Last 2026 Q2 | Exit 0.00% | 8,659 | $306K | History |
Insider trades
Open-market buys and sales by ROIV's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $779M sold by 10 insiders outside a trading plan
- $174M sold by 4 insiders under 10b5-1 plans
-
Keith S. Manchester DirectorSale$53.5M 1,381,762 shares at $38.75 19% of stakeTraded Nov 16–17 Filed Nov 18
-
Richard Pulik CFOSale$12.5M 300,000 shares at $41.58 58% of stakeTraded Nov 10–11 Filed Nov 12
-
Eric Venker CEOPlanned sale$7.6M 187,943 shares at $40.53 19% of stakeTraded Nov 10 Filed Nov 12
-
Eric Venker CEOPlanned sale$7.3M 200,000 shares at $36.31 17% of stakeTraded Nov 3 Filed Nov 5
-
Eric Venker CEOPlanned sale$7.3M 200,000 shares at $36.59 14% of stakeTraded Oct 28 Filed Oct 30
-
Eric Venker CEOPlanned sale$7M 200,000 shares at $35.11 13% of stakeTraded Oct 20 Filed Oct 22
-
Melissa B. Epperly DirectorPlanned sale$641K 17,750 shares at $36.10 54% of stakeTraded Oct 1 Filed Oct 5
-
Eric Venker CEOPlanned sale$7.3M 200,000 shares at $36.62 11% of stakeTraded Sep 30 Filed Oct 2
-
Melissa B. Epperly DirectorPlanned sale$196K 4,938 shares at $39.74 33% of stakeTraded Sep 15 Filed Sep 17
-
Meghan Fitzgerald DirectorPlanned sale$203K 5,112 shares at $39.74 12% of stakeTraded Sep 15 Filed Sep 17
-
Meghan Fitzgerald DirectorPlanned sale$798K 20,000 shares at $39.90 32% of stakeTraded Sep 8 Filed Sep 10
-
Eric Venker CEOPlanned sale$7.2M 200,000 shares at $35.77 11% of stakeTraded Aug 28 Filed Sep 1
-
Mayukh Sukhatme President & CIOSale$12.4M 335,174 shares at $36.88 1.8% of stakeTraded Aug 19–21 Filed Aug 21
Also filed in the last 12 months, not counted as buying or selling: 44 option exercises, 41 share withholdings for taxes, 38 other transactions, 21 stock grants, 2 sales to cover taxes, and 1 gift.
Congress
1 member of Congress traded ROIV in the last three years: 2 buys and 2 sales.
-
Lisa C. McClain
Sell
$1K–$15K
Oct 31, 2025
filed Nov 21, 2025
-
Lisa C. McClain
Buy
$1K–$15K
Oct 30, 2025
filed Nov 21, 2025
-
Lisa C. McClain
Sell
$1K–$15K
Oct 30, 2025
filed Nov 21, 2025
-
Lisa C. McClain
Buy
$1K–$15K
Jun 17, 2025
filed Aug 13, 2025
SEC filings
Recent issuer filings from EDGAR, 7 shown.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon